原发性肝癌患者血清IL-17A、IL-6、IP-10水平与临床病理学特征及预后的关系

The relationship between serum IL-17A,IL-6,IP-10 levels and their clinicopathological features and prognosis in patients with primary liver cancer

目的 分析原发性肝癌(primary liver cancer,PLC)患者血清白介素-17A(interleukin-17A,IL-17A)、白介素-6(interleukin-6,IL-6)、干扰素γ诱导蛋白-10(interferon γ-inducible protein-10,IP-10)水平与其临床病理学特征及预后的关系。方法 纳入2021年6月至2022年12月西安市长安区医院收治的PLC患者106例(病例组),并纳入同期本院体检的健康人106例(对照组),比较两组研究对象血清IL-17A、IL-6、IP-10水平,观察病例组内不同临床病理学特征及患者间血清IL-17A、IL-6、IP-10水平差异。随访3个月,根据不同预后分组,对比预后良好组与预后不良组血清IL-17A、IL-6、IP-10水平差异,并进行预后不良的Logistics回归分析。结果 病例组血清IL-17A、IL-6、IP-10水平显著高于对照组(P<0.05);病例组内Ⅲ及Ⅳ期、肿瘤直径≥5 cm、低分化、有淋巴结转移的患者血清IL-17A、IL-6、IP-10水平显著高于Ⅰ、Ⅱ期、肿瘤直径<5 cm、中及高分化、无淋巴结转移的患者(P<0.05);预后不良组血清IL-17A、IL-6、IP-10水平显著高于预后良好组(P<0.05);Logistics回归分析提示IL-17A、IL-6、IP-10均为原发性肝癌患者预后不良的危险因素(OR>1,P<0.05)。结论 PLC患者血清IL-17A、IL-6、IP-10水平高于健康人,且血清IL-17A、IL-6、IP-10水平与患者临床病理学特征具有相关性,是影响患者预后的独立危险因素。

Objective To analyze serum interleukin-17A(IL-17A),interleukin-6(IL-6),interferonγ-inducible protein-10(IP-10)in patients with primary liver cancer(PLC)The relationship between the level and its clinicopathological features and prognosis.Methods A total of 106 PLC patients(case group)who were admitted to Chang'an District Hospital of Xi'an from June 2021 to December 2022 were included,and 106 healthy people(control group)who underwent physical examination in same hospital during the same period were included.The serum levels of IL-17A,IL-6,and IP-10 between two study subjects were compared,and the differences in serum IL-17A,IL-6,and IP-10 levels among patients with different clinicopathological features within the case group were observed.Follow up for 3 months,based on different prognosis groups,the differences in serum IL-17A,IL-6,and IP-10 levels between the group with good prognosis and the group with poor prognosis were compared,and logistic regression analysis for poor prognosis was conducted.Results The serum levels of IL-17A,IL-6,and IP-10 in the case group were significantly higher than those in the control group(P<0.05).The serum IL-17A,IL-6,and IP-10 levels in patients with stageⅢandⅣtumors,tumor diameter≥5 cm,low differentiation,and lymph node metastasis in the case group were significantly higher than those in patients with stageⅠandⅡtumors with diameter<5 cm,medium and high differentiation,and no lymph node metastasis(P<0.05).The serum levels of IL-17A,IL-6,and IP-10 in the poor prognosis group were significantly higher than those in the good prognosis group(P<0.05).Logistic regression analysis showed that IL-17A,IL-6,and IP-10 were all risk factors for poor prognosis in patients with primary liver cancer(OR>1,P<0.05).Conclusion Serum levels of IL-17A,IL-6,and IP-10 in patients with PLC are higher than those in healthy people,and the serum levels of IL-17A,IL-6,and IP-10 are correlated with the clinical and pathological characteristics of patients,and are independent risk factors affecting patient prognosis.